Potential ADCC/ADCP Effects of a Humanized Anti-human Cripto-1 Antibody
Anticancer Research · 2026-08 · 46 (8) · 4267-4277
DOI: 10.21873/anticanres.18285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 29.07.2026. Verfasst von Kazuki Kumon und 2 weiteren Autor:innen. Beteiligte Einrichtung: GSP Enterprise, Inc., Osaka, Japan. Hauptthemen laut MEDLINE: Antibody-Dependent Cell Cytotoxicity, GPI-Linked Proteins, Neoplasm Proteins, Phagocytosis.
Abstract (Originalsprache)
Background/Aim: Cripto-1 (CR-1) is recognized as a potential theranostic biomarker expressed on the surface of tumor cells, including cancer stem cells. We previously reported a humanized anti-human CR-1 antibody (ah2CR1-Ab35), derived from a phage display library, that demonstrated growth inhibition in cancer-derived cells. In this study, the potential of this antibody was evaluated for its ability to mediate antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) in CR-1–expressing cells. Materials and Methods: Jurkat cells recombinantly expressing CD16a, low-affinity CD16a, and CD32a, in which cytoplasmic signaling was engineered using a luciferase reporter system, were employed as effector cells to target MDA-MB-231, MIA-Paca-2, LS 174T, and HEK293 cells, in which CR-1 expression was enhanced using CR-1 expression plasmids. Anti-sense CR-1 expression plasmids were also constructed and independently introduced into each cell line to establish background controls by suppressing endogenous CR-1 expression. Photon counts from luciferase reactions stimulated by the anti-CR-1 antibody were then measured after subtracting background-derived signals.
Results
Both ADCC and ADCP effects mediated by the anti-CR-1 antibody were successfully demonstrated in a dose-dependent manner. The antibody exhibited an EC50 of approximately 1 μM in MDA-MB-231 cells and 1-4 μM in MIA-Paca-2 cells, whereas in LS 174T cells, the EC50 ranged from 1 to 4 μM for ADCC but was not clearly determined for ADCP owing to the low photon counts.
Conclusion
The humanized anti-human CR-1 antibody has been suggested to mediate ADCC and ADCP effects in CR-1–expressing cells. However, these effects did not appear to correlate with CR-1 expression levels. The efficacy of CR-1 targeting via ADCC and ADCP effects may depend on the characteristics of the target cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSP Enterprise, Inc., Osaka, Japan.
- Department of Cancer Stem Cell Engineering, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan.
- ABIOTECH Co., Ltd., Seoul, Republic of Korea.
- Department of Cancer Stem Cell Engineering, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan; mseno@okayama-u.ac.jp.
Zitieren
APA
Kumon, K., Jang, M. H., & Seno, M. (2026). Potential ADCC/ADCP Effects of a Humanized Anti-human Cripto-1 Antibody. Anticancer Research, 46(8), 4267-4277. https://doi.org/10.21873/anticanres.18285
Vancouver
Kumon K, Jang MH, Seno M. Potential ADCC/ADCP Effects of a Humanized Anti-human Cripto-1 Antibody. Anticancer Research. 2026;46(8):4267-4277. doi:10.21873/anticanres.18285
BibTeX
@article{Kumon2026,
author = {Kumon, Kazuki and Jang, Myeong Hee and Seno, Masaharu},
title = {Potential ADCC/ADCP Effects of a Humanized Anti-human Cripto-1 Antibody},
journal = {Anticancer Research},
year = {2026},
volume = {46},
number = {8},
pages = {4267--4277},
doi = {10.21873/anticanres.18285}
}
EUVIMED